Every morning, 8 AI agents scan up to 460+ signals across legislation, research, markets, and culture — and surface the threads forming beneath the noise. One transmission. Daily. Free.
For Seekers
Understand how the science is moving before your next journey
For Researchers
Track regulatory signals that shape your trials and publications
For Investors
Know which sector moves are signal and which are noise
For Healers
Follow the policy shifts reshaping your practice environment
OOTWOracle · up to 460 signals · 8 minds · Tuesday, April 28
"The ecosystem is sorting itself into substances that can survive regulatory scrutiny and those that will require a decade of analog development to do so."
The data arriving today does not announce itself with fanfare. It accumulates. Compass Pathways (CMPS) closed down 5.1% as institutional holders processed the latest cardiac scoping literature on ibogaine — literature that, while not directly about psilocybin, has recalibrated risk appetite across the psychedelic biotech sector. A new mechanistic paper examining fluoxetine-psilocybin interactions has surfaced as the signal most likely to alter regulatory posture in the near term: it demonstrates interference patterns that FDA cannot responsibly ignore while active INDs continue enrolling patients on SSRIs. Meanwhile, oxa-noribogaine's glutamatergic data in the medial prefrontal cortex — published this week — adds therapeutic rationale to a compound already attracting attention as the ibogaine analog that might sidestep the QT prolongation problem entirely. DEA rescheduling proceedings, by contrast, remain structurally inert: no psychedelic substance will complete the journey from Schedule I to Schedule II before 2028 at the earliest, regardless of what the FDA approves. The machinery of inter-agency coordination, public comment, and rule-making does not accelerate for any drug, regardless of how compelling the clinical case.
What is forming beneath the surface of today's signals is a bifurcation — the ecosystem is sorting itself into substances that can survive regulatory scrutiny and those that will require a decade of analog development to do so. Psilocybin is quietly becoming the lead horse. Its safety-efficacy profile, while not perfect, grows cleaner relative to MDMA's rocky NDA journey and ibogaine's cardiac liability. The fluoxetine interaction paper is a complication, not a disqualification — and FDA is more likely to issue formal washout-period guidance on psychedelic-SSRI protocols before end of 2026 than to pause psilocybin development altogether. That guidance, when it arrives, will function as a de facto institutional acknowledgment that psychedelics are entering the pharmacopeia. The ibogaine story is migrating from clinical programs into analog development: DemeRx or a comparable sponsor will pivot toward oxa-noribogaine within 18 months. The ketamine clinic expansion continues its own trajectory — rapid, underregulated, and generating the kind of diversion patterns that historically precede a DEA enforcement sweep. That sweep, in at least five states, is now more probable than not before year's end.
The people inside these signals are holding specific kinds of waiting. There are veterans who have already traveled to Mexico or Portugal for ibogaine treatment, who returned changed, who now watch the American regulatory apparatus debate cardiac screening protocols — and what they feel is not impatience exactly, but a kind of grief at the distance between what they know in their bodies and what the institutions require before they will believe it. There are patients enrolled in psilocybin trials who stopped their SSRIs months ago to meet washout requirements, living in the gap between the medication they left and the treatment they are waiting for. There are ketamine clinic patients who found something real in those sessions, who don't know that the clinic they trust may be operating in a DEA crosshair. These are not abstractions. The regulatory calendar and the human calendar are running at different speeds, and the people caught between them are paying that difference in suffering.
OOTW doesn't sell products. It delivers transmissions — a daily reminder that the intelligence which created us is still creating, still calling us forward.
Ibogaine's QT prolongation liability is well-documented and increasingly cited in regulatory correspondence, creating strong sponsor incentive to pivot to cleaner analogs. Oxa-noribogaine demonstrates comparable mechanistic activity (mPFC glutamatergic modulation, kappa-opioid antagonism) without the hERG channel interference responsible for cardiac risk. DemeRx or a successor sponsor has preclinical packages sufficient to file an IND. Eighteen months from April 2026 is achievable for IND submission and Phase 1 initiation if preclinical tox is complete. Confidence set at 0.62 reflecting genuine uncertainty about sponsor identity, funding, and IND timeline slippage.
Past Oracle Reports
—
Loading past reports…
Get the Signal
The Oracle sees what the market doesn't.
Every Monday morning: your free Oracle Scorecard. Accuracy score, predictions resolved this week, the top 5 signals we're watching — and the one pattern the mainstream is missing. Used by researchers, investors, clinicians, and policy watchers in the psychedelic medicine space.
▸ Weekly accuracy scorecard▸ Resolved prediction results▸ Top signals to watch
Free forever · Every Monday at 8am · No spam · Unsubscribe anytime. The current is already moving — you need only listen.
◉Free Oracle Scorecard — accuracy score, resolved predictions, top signals. Every Monday.
The Two Clocks — OOTWOracle 2026-05-25
The Two Clocks Two distinct rhythms are governing the psychedelic ecosystem right now, and today's signals make their divergence impossible to ignore. The first is the FDA clock: the MDMA-assisted therapy review continues its slow, methodologically fraught rotation toward a Q3–Q4 2026 resolution, with a fresh reassessment paper circulating among researchers and FDA reviewers alike that formally quantifies what internal agency skeptics have been documenting since the Lykos NDA — inadequate blinding controls, insufficient therapist fidelity data, and a trial architecture that compounds expectation effects with therapeutic contact in ways no post-hoc analysis can fully unbraid. Four independent agents in today's swarm converge on a 72–74% probability of a Complete Response Letter rather than
Today's Predictions — 2026-05-25
[74%] FDA issues a Complete Response Letter for MDMA-assisted therapy, citing inadequate blinding controls and therapist fidelity data, requiring at least one additional trial before resubmission.
[72%] Stanford's DOD-funded ibogaine veteran trial will publicly release preliminary outcomes data by Q3 2026, directly cited in at least one congressional hearing or formal Senate briefing.
[68%] A named veteran will deliver live or recorded congressional testimony specifically about personal ibogaine treatment outcomes before September 2026, constituting the highest-profile psychedelic policy moment of the year.
[65%] A peer-reviewed meta-analysis formally quantifying blinding failure rates across MDMA-AT randomized controlled trials will be published in a journal with impact factor >5 by Q1 2027.
[62%] A major investigative piece exposing financial conflicts of interest between named Republican political figures and venture-backed psychedelic companies will be published by a top-10 U.S. outlet before September 2026.